TGFB2 and idiopathic pulmonary fibrosis: Our findings are consistent with published data showing that nintedanib inhibited TGF–β2 (10 ng / ml)–induced differentiation of primary human lung fibroblasts (from IPF patients) to myofibroblast in an α–smooth muscle actin mRNA expression assay [24].